REG - Hikma Pharmaceutical - Director/PDMR Shareholding

Hikma PharmaceuticalsAnnouncement

06/09/2019 15:30

RNS Number : 5610L
Hikma Pharmaceuticals Plc
06 September 2019
 


Notification and public disclosure of transactions by person discharging managerial responsibilities
 




1


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Said Darwazah




2


Reason for the notification




a)


Position/status


Executive Chairman




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Hikma Pharmaceuticals PLC




b)


LEI


549300BNS685UXH4JI75




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument and identification code


Description: Ordinary shares of 10 pence each
ID Code: GB00B0LCW083




b)


Nature of the transaction
 


Disposal of 150,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC by Banque Lombard Odier & Cie SA




c)


Price(s) and volume(s)


Price(s): £20.56
Volume(s): 49,826
Price(s): £19.85
Volume(s): 25,000
Price(s): £19.82
Volume(s): 25,000
Price(s): £19.84
Volume(s): 25,000
Price(s): £19.82
Volume(s): 25,174




d)


Aggregated information


Aggregated volume: 150,000
Price: £20.07
Total: £3,011,121




e)


Date of the transaction


4 and 6 September 2019




f)


Place of the transaction


London Stock Exchange (XLON)




Peter Speirs, Company Secretary, Responsible for releasing this announcement
6 September 2019




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBSGDCXDGBGCL